The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

The removal request is based on a ‘comprehensive review of available data’ that showed no increased risk of suicidal ideation and behavior.

After Novo Nordisk’s popular obesity medicine Wegovy went into short supply, people turned to the company’s first-generation weight-loss drug, Saxenda, for treatment. Now, the company is struggling to ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

COPENHAGEN (Reuters) -Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity ...

(CNN)– The Food and Drug Administration (FDA) wants suicide warnings to be taken off of some popular weight-loss medications.

A new injectable drug, aimed at helping obese and seriously overweight people who have other weight-related health conditions, has proven effective in a new round of testing. The drug, called ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

The GLP-1 receptor agonist, which was first approved for adults in December 2014, is now a treatment option for adolescents with obesity ages 12-17 as adjunct to diet and exercise. More specifically, ...